

国内版

国际版



Durable response to pulsatile icotinib for central nervous syste



All

Images

Videos

开启取词

11,500 Results

Any time ▾

"Pulsatile" high-dose weekly erlotinib for CNS metastases ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223088>

Aug 24, 2011 · "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant **non-small cell lung cancer** Christian Grommes , Geoffrey R. Oxnard , Mark G. Kris , Vincent A. Miller , William Pao , Andrei I. Holodny , Jennifer L. Clarke , and Andrew B. Lassman

Durable response to osimertinib in EGFR mutated T790M ...

<https://www.sciencedirect.com/science/article/pii/S0169500217305482>

Leptomeningeal (LM) metastases in non-small cell lung cancer (NSCLC) has a poor prognosis, with no established standard of care treatment. In patients with **epidermal growth factor receptor (EGFR)** mutations, LM metastases has been noted in up to 10% of patients .

Cited by: 3

Author: Anna Chalmers, Leif Jensen, Wallace Ak...

Publish Year: 2017

Afatinib helped overcome subsequent resistance to ...

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5915-7> ▾

Jul 17, 2019 · This study aimed to report a case baring acquired EGFR L858R/L718Q mutation in the central nervous system induced by osimertinib, which was successfully overcome using afatinib. A 65-year-old female patient was diagnosed with **stage IV non-small-cell lung adenocarcinoma** with **synchronic brain metastasis** in February 2015.

Cited by: 1

Author: Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yu...

Publish Year: 2019

Epidermal Growth Factor Receptor Tyrosine Kinase ...

theoncologist.alphamedpress.org/content/23/10/1199.full

Oct 01, 2018 · **Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer** Manmeet S. Ahluwalia a , Kevin Becker b and

Cited by: 5

Author: Manmeet S. Ahluwalia, Kevin Becker, Be...

Publish Year: 2018

"Pulsatile" high-dose weekly erlotinib for CNS metastases ...

<https://academic.oup.com/neuro-oncology/article/13/12/1364/1080532> ▾

Aug 24, 2011 · "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant **non-small cell lung cancer** Christian Grommes. ... had both documented T790M and was re-evaluated systemically following **pulsatile** therapy. **Best response** in this case was ... Development of central

Match Overview

1	Crossref 70 words Huiying Li, Tingting Yu, Mingmin Huang, Aibin Guo, Xiaoping Qian, Zhenyu Yin. "	4%
2	Internet 30 words crawled on 03-Oct-2019 www.wjgnet.com	2%
3	Crossref 12 words Ya-Lan Wu, Qian Zhao, Lei Deng, Yan Zhang, Xiao-Juan Zhou, Yan-Ying Li, Min Yu, Lin Zhou, Bing-Wen Zou, You Lu, Yo	1%
4	Internet 12 words crawled on 14-Nov-2017 clincancerres.aacrjournals.org	1%
5	Internet 11 words crawled on 07-Sep-2019 tessera.spandidos-publications.com	1%
6	Crossref 11 words Xingsheng Hu, Li Zhang, Yuankai Shi, Caicun Zhou et al. "The Efficacy and Safety of Icotinib in Patients with Advanced	1%
7	Crossref 11 words Annick Wong. "The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastase ...	1%
8	Crossref 10 words Shingyoji, Masato, and Toshihiko Iuchi. "Considerations on the management of EGF receptor-TKIs for brain metastase ...	1%
9	Crossref 10 words Che, Wen-cheng, Qi Zang, Qiang Zhu, Tian-chang Zhen, Gong-zhang Su, Peng Liu, and Huai-jun Ji. "Lipoma-Like Bro	1%
10	Internet 10 words crawled on 25-Nov-2017 ascopubs.org	1%
11	Crossref 10 words C. Cotto, J. Berille, P.J. Souquet, R. Riou, B. Croisile, F. Turjman, B. Giroux, J. Brune, V. Trillet-Lenoir. "A phase II trial of	1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 51951

Manuscript Type: CASE REPORT

Durable response to pulsatile icotinib for central nervous system metastases from EGFR-mutated non-small cell lung cancer: A case report

Hui-Ying Li, Yu Xie, Ting-Ting Yu, Yong-Juan Lin, Zhen-Yu Yin

Abstract

BACKGROUND

Central nervous system (CNS) metastases are a catastrophic complication of non-small cell lung cancer (NSCLC), including brain and leptomeningeal



11,500 Results

Any time ▾

Durable response to osimertinib in EGFR mutated T790M ...

<https://www.sciencedirect.com/science/article/pii/S0169500217305482>

Leptomeningeal (LM) **metastases** in non-small cell lung cancer (NSCLC) has a poor prognosis, with no established standard of care treatment. In patients with **epidermal growth factor receptor (EGFR)** mutations, LM **metastases** has been noted in up to 10% of patients .

Cited by: 3

Author: Anna Chalmers, Leif Jensen, Wallace Ak...

Publish Year: 2017

"Pulsatile" high-dose weekly erlotinib for CNS metastases ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223088>

Aug 24, 2011 · "Pulsatile" high-dose weekly erlotinib for CNS **metastases** from EGFR mutant non-small cell lung cancer Christian Grommes , Geoffrey R. Oxnard , Mark G. Kris , Vincent A. Miller , William Pao , Andrei I. Holodny , Jennifer L. Clarke , and Andrew B. Lassman

Cited by: 296

Author: Christian Grommes, Geoffrey R. Oxnard, ...

Publish Year: 2011

Durable brain response with pulse-dose crizotinib and ...

<https://www.sciencedirect.com/science/article/pii/S0967586815005755>

Crizotinib achieves excellent systemic control in anaplastic lymphoma kinase-rearranged (ALK+) non-small cell lung cancer (NSCLC); however, **central nervous system (CNS) metastases** frequently occur as an early event. Whole **brain irradiation**, the standard treatment, results in **neurocognitive impairment**.

Cited by: 5

Author: Elizabeth Dudnik, Tali Siegal, Tali Siegal, ...

Publish Year: 2016

Afatinib helped overcome subsequent resistance to ...

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5915-7> ▾

Jul 17, 2019 · This study aimed to report a case baring acquired EGFR L858R/L718Q mutation in the central nervous system induced by osimertinib, which was successfully overcome using afatinib. A 65-year-old female patient was diagnosed with **stage IV non-small-cell lung adenocarcinoma** with **synchronic brain metastasis** in February 2015.

Cited by: 1

Author: Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yu...

Publish Year: 2019